Skip to main content

Table 2 Clinical and radiological characteristics of MS patients

From: The emerging role of serum zinc in motor disability and radiological findings in patients with multiple sclerosis

  Patients in relapse (n = 25) Patients in remission (n = 25) P value
Disease duration [mean(SD)] 4.6800 (4.69) 5.52 (5.06) 0.545
Number of relapses in the last 2 years [mean (SD)] 1.52 (0.59) 1.36 (0.7) 0.385
Total number of relapses [mean (SD)] 2.6 (1.55) 3.28 (2.05) 0.193
DMDs Monthly methylprednisolone [n (%)] 18 (72.0%) 13 (52.0%) 0.01*
Interferon beta-1a (Avonex) [n (%)] 0 (0.0%) 7 (28.0%)
Interferon beta-1b (Betaferon) [n (%)] 5 (20.0%) 1 (4.0%)
Interferon beta-1a (Rebif) [n (%)] 1 (4.0%) 4 (16.0%)
Azathioprine [n (%)] 1 (4.0%) 0 (0.0%)
EDSS before pulse steroids [mean (SD)] 4.08 (2.06) _ _
EDSS after pulse steroids [mean (SD)] 2.9400 (1.72) 2.88 (1.29) 0.889
MRS [mean (SD)] 0.3200 (0.63) 0.2 (0.5) 0.458
MFIS[mean (SD)] 7.24 (4.81) 6.56 (4.19) 0.596
MRI lesion load [mean (SD)] 11.0400 (6.29) 11.0800 (5.35) 0.980
  1. DMDs disease modifying drugs, EDSS Expanded Disability Status Scale, MRS modified RIO score, MFIS modified fatigue impact scale, MRI magnetic resonance imaging
  2. *P value < 0.05 (significant)